New drug trial targets hardening skin in scleroderma patients
NCT ID NCT05198557
Summary
This study is testing whether an investigational drug called MT-0551 is better than a placebo at reducing skin thickening in people with systemic sclerosis (scleroderma). The 80 participants will receive either the drug or a placebo for 26 weeks, and researchers will measure changes in skin thickness and lung function. The goal is to see if MT-0551 can help control this chronic autoimmune disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
St. Marianna University Hospital
Kawasaki-shi, Kanagawa, 216-8511, Japan
-
The University of Tokyo Hospital
Bunkyo-ku, Tokyo, 113-8655, Japan
-
University of Fukui Hospital
Yoshida-gun, Fukui, 910-1193, Japan
Conditions
Explore the condition pages connected to this study.